In the context of Multiple Myeloma, notable antigens such as CD19, CD38, CD138, BCMA (B-cell Maturation Antigen), Kappa (κ) light chain, SLAMF7, NKG2D, and GPRC5D have been identified as effective targets for CAR T-cell therapy (Fig. 3). Here, CD38 is linked to AL amyloidosis.